根除幽门螺杆菌在原发免疫性血小板减少症中的应用进展

Progresses of Helicobacter pylori eradication in patients with primary immune thrombocytopenia

原发免疫性血小板减少症(ITP)是一种免疫介导的血小板过度破坏及生成减少所致的出血性疾病,其发病机制尚未完全阐明,临床治疗首选糖皮质激素,有效率约60%,然而部分难治性ITP患者应用激素治疗效果欠佳。近年来研究报道抗幽门螺杆菌(Hp)感染治疗对部分ITP患者有效,同时也有相关研究对之提出争议,关于Hp如何参与ITP发生的作用机制也尚未阐明,本文就Hp与ITP关系的临床研究进展作一综述。

Primary immune thrombocytopenia(ITP) is characterized by immune-mediated diseases with the platelet destruction and decreased production. The pathogenic mechanism of ITP is unclear. Glucocorticoids-based regimens are commonly used as the initial treatment(effective rate is about 60%), however, for some refractory ITP, the curative effect is poor. In recent years, some researchers have found that the eradication of Helicobacter pylori(Hp) infection has been variably associated with a platelet response in patients with ITP, but it also has different opinions. The mechanism of how HP participates in ITP is not fully elucidated. This article made a summary about the research progress of the relation between HP and ITP.